Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28878914 | 0.84 | LMNA (0.31) | F2ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL23704505 | 0.83 | — | — | |
| SCHEMBL30097402 | 0.78 | F2 (0.31) | F2ALDH1A1LMNAHSD17B10TNIK | |
| SCHEMBL23711611 | 0.78 | F2 (0.31) | F2ALDH1A1LMNAHSD17B10TNIK | |
| SCHEMBL25144054 | 0.73 | LMNA (0.36) | F2ALDH1A1LMNAHSD17B10MAPT | |
| SCHEMBL23718561 | 0.72 | F2 (0.31) | F2ALDH1A1LMNAHSD17B10TNIK | |
| SCHEMBL23711797 | 0.72 | ALDH1A1 (0.30) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL30097870 | 0.72 | F2 (0.31) | F2ALDH1A1LMNAHSD17B10TNIK | |
| SCHEMBL2910688 | 0.69 | LMNA (0.47) | ALDH1A1LMNAHSD17B10MAPTKMT2A | |
| SCHEMBL25480031 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| EP-4097108-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | F2 4152/4885ALDH1A1 1848/4885LMNA 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.